WO2002000727A3 - Gp286 nucleic acids and polypeptides - Google Patents

Gp286 nucleic acids and polypeptides Download PDF

Info

Publication number
WO2002000727A3
WO2002000727A3 PCT/US2001/020038 US0120038W WO0200727A3 WO 2002000727 A3 WO2002000727 A3 WO 2002000727A3 US 0120038 W US0120038 W US 0120038W WO 0200727 A3 WO0200727 A3 WO 0200727A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
domain
nucleic acids
cell
protein
Prior art date
Application number
PCT/US2001/020038
Other languages
French (fr)
Other versions
WO2002000727A2 (en
Inventor
John P Carulli
Alexander V Lukashin
Daniel R Kilburn
Punam Mathur
Original Assignee
Biogen Inc
John P Carulli
Alexander V Lukashin
Daniel R Kilburn
Punam Mathur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, John P Carulli, Alexander V Lukashin, Daniel R Kilburn, Punam Mathur filed Critical Biogen Inc
Priority to AU2001272982A priority Critical patent/AU2001272982B2/en
Priority to AU7298201A priority patent/AU7298201A/en
Priority to NZ523477A priority patent/NZ523477A/en
Priority to EP01952197A priority patent/EP1297137A2/en
Priority to JP2002505849A priority patent/JP2004501630A/en
Priority to CA002412610A priority patent/CA2412610A1/en
Publication of WO2002000727A2 publication Critical patent/WO2002000727A2/en
Publication of WO2002000727A3 publication Critical patent/WO2002000727A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

An isolated polynucleotide encoding a novel immunoglobulin superfamily member named GP286 is provided. GP286 has a predicted single membrane spanning domain and one immunoglobulin (Ig) domain in the extracellular portion of the protein. The protein structure and tissue distribution of GP286 indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the immune system. Provided by the invention are isolated GP286 related polynucleotides and polypeptides, vectors, and host cells comprisingany of the above, antibodies directed to GP286, cells which produce such antibodies, and related diagnostic and therapeutic methods.
PCT/US2001/020038 2000-06-23 2001-06-22 Gp286 nucleic acids and polypeptides WO2002000727A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001272982A AU2001272982B2 (en) 2000-06-23 2001-06-22 GP286 nucleic acids and polypeptides
AU7298201A AU7298201A (en) 2000-06-23 2001-06-22 Gp286 nucleic acids and polypeptides
NZ523477A NZ523477A (en) 2000-06-23 2001-06-22 GP286 nucleic acids and polypeptides
EP01952197A EP1297137A2 (en) 2000-06-23 2001-06-22 Gp286 nucleic acids and polypeptides
JP2002505849A JP2004501630A (en) 2000-06-23 2001-06-22 GP286 nucleic acids and polypeptides
CA002412610A CA2412610A1 (en) 2000-06-23 2001-06-22 Gp286 nucleic acids and polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21363000P 2000-06-23 2000-06-23
US60/213,630 2000-06-23
US28381301P 2001-04-13 2001-04-13
US60/283,813 2001-04-13

Publications (2)

Publication Number Publication Date
WO2002000727A2 WO2002000727A2 (en) 2002-01-03
WO2002000727A3 true WO2002000727A3 (en) 2003-01-03

Family

ID=26908248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020038 WO2002000727A2 (en) 2000-06-23 2001-06-22 Gp286 nucleic acids and polypeptides

Country Status (6)

Country Link
EP (1) EP1297137A2 (en)
JP (1) JP2004501630A (en)
AU (2) AU7298201A (en)
CA (1) CA2412610A1 (en)
NZ (1) NZ523477A (en)
WO (1) WO2002000727A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5883384B2 (en) * 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー How to regulate immune function
US20220154170A1 (en) * 2019-03-01 2022-05-19 Fred Hutchinson Cancer Research Center Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011014A1 (en) * 1998-08-25 2000-03-02 Human Genome Sciences, Inc. 49 human secreted proteins
WO2000029623A2 (en) * 1998-11-17 2000-05-25 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2001077291A2 (en) * 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
WO2001093983A1 (en) * 2000-06-02 2001-12-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011014A1 (en) * 1998-08-25 2000-03-02 Human Genome Sciences, Inc. 49 human secreted proteins
WO2000029623A2 (en) * 1998-11-17 2000-05-25 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2001077291A2 (en) * 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
WO2001093983A1 (en) * 2000-06-02 2001-12-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 29 September 1996 (1996-09-29), S. HADANO: "Human brain cDNA, composite sequence 033-00-1", XP002212973, retrieved from EBI, HINXTON, UK Database accession no. D44637 *
DATABASE EMBL [online] 4 August 1999 (1999-08-04), DOE JOINT GENOME INSTITUTE STANFORD HUMAN GENOME CENTER: "Homo sapiens chromosome 19 clone CTB-144D21, complete sequence", XP002212971, retrieved from EBI, HINXTON, UK. Database accession no. AC008616 *
DATABASE EMBL [online] 6 July 2000 (2000-07-06), S. H. GOH ET AL: "DP0373 KRIBB DP intrathymic T-cell cDNA library Homo sapiens cDNA 3', mRNA sequence", XP002212974, retrieved from EBI, HINXTON, UK. Database accession no. AW063767 *
DATABASE EMBL [online] 9 April 1998 (1998-04-09), NCI-CGAP: "ok05h07.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1506973", XP002212972, retrieved from EBI, HINXTON, UK Database accession no. AA905516 *
S.H. GOH ET AL: "Gene expression profile and identification of diffrentially expressed transcripts during human intrathymic T-cell development by cDNA sequencing analysis", GENOMICS, vol. 70, no. 1, 2000, pages 1 - 18 *
UNPUBLISHED *

Also Published As

Publication number Publication date
EP1297137A2 (en) 2003-04-02
AU7298201A (en) 2002-01-08
JP2004501630A (en) 2004-01-22
WO2002000727A2 (en) 2002-01-03
CA2412610A1 (en) 2002-01-03
AU2001272982B2 (en) 2006-08-24
NZ523477A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
WO1997033995A3 (en) Extracellular matrix signalling molecules
WO1999020756A3 (en) Human toll homologues
EP0871726A4 (en) Multispecific chimeric receptors
WO1998050554A3 (en) Enterococcus faecalis polynucleotides and polypeptides
WO2001032709A3 (en) Polypeptides with non-natural primary signalling motifs
WO2003025015A3 (en) A soluble toll-like receptor
WO1996040040A3 (en) Thrombin receptor homolog
WO2002000727A3 (en) Gp286 nucleic acids and polypeptides
WO2001098360A3 (en) Gp354 nucleic acids and polypeptides
WO1999025832A8 (en) Toso
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
WO1998025956A3 (en) Human GTP-binding proteins
WO1997044447A3 (en) Transcriptional activation system, activators, and uses therefor
DE69831141D1 (en) Z2-19A, A HUMOLOGICAL HOMOLOGOUS OF THE PROTEIN 2-19
EP1780219A3 (en) Protein S polypeptides and uses thereof
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2003000021A3 (en) Pancam nucleic acids and polypeptides
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
WO1999057277A3 (en) Basb019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO2000022121A3 (en) Ion channels, in particular vanilloid receptor-like (vr-l) receptor
WO2003034275A3 (en) Chimeric glycosylphosphatidylinositol containing peptides
CA2112701A1 (en) Proteins s polypeptides and uses thereof
WO2004003165A3 (en) Novel polynucleotide and polypeptide sequences and uses thereof
WO2002055700A8 (en) Human genes and gene expression products isolated from human prostate
EP1757618A3 (en) Angiogenesis-associated proteins, and nucleic acids encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 505849

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2412610

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001272982

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 523477

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001952197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10312495

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001952197

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 523477

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523477

Country of ref document: NZ